Kaur, SharanjotVerma, HarkomalKaur, SukhchainGangwar, PrabhakarYadav, AnuradhaYadav, BhartiRao, RashmiDhiman, MonishaMantha, Anil Kumar2024-01-212024-08-132024-01-212024-08-132023-07-28885749010.1007/s11011-023-01265-9http://10.2.3.109/handle/32116/3487Small non-coding RNAs (miRNAs) regulate gene expression by binding to mRNA and mediating its degradation or inhibiting translation. Since miRNAs can regulate the expression of several genes, they have multiple roles to play in biological processes and human diseases. The majority of miRNAs are known to be expressed in the brain and are involved in synaptic functions, thus marking their presence and role in major neurodegenerative disorders, including Alzheimer�s disease (AD). In AD, amyloid beta (A?) plaques and neurofibrillary tangles (NFTs) are known to be the major hallmarks. The clearance of A? and tau is known to be associated with miRNA dysregulation. In addition, the ?-site APP cleaving enzyme (BACE 1), which cleaves APP to form A?, is also found to be regulated by miRNAs, thus directly affecting A? accumulation. Growing evidences suggest that neuroinflammation can be an initial event in AD pathology, and miRNAs have been linked with the regulation of neuroinflammation. Inflammatory disorders have also been associated with AD pathology, and exosomes associated with miRNAs are known to regulate brain inflammation, suggesting for the role of systemic miRNAs in AD pathology. Several miRNAs have been related in AD, years before the clinical symptoms appear, most of which are associated with regulating the cell cycle, immune system, stress responses, cellular senescence, nerve growth factor (NGF)�signaling, and synaptic regulation. Phytochemicals, especially polyphenols, alter the expression of various miRNAs by binding to miRNAs or binding to the transcriptional activators of miRNAs, thus control/alter various metabolic pathways. Awing to the sundry biological processes being regulated by miRNAs in the brain and regulation of expression of miRNAs via phytochemicals, miRNAs and the regulatory bioactive phytochemicals can serve as therapeutic agents in the treatment and management of AD. � 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.en-USAlzheimer�s diseaseAmyloid betamiRNAsNeurodegenerationPhytochemicalsReviewhttps://link.springer.com/10.1007/s11011-023-01265-9